Mass Tort MDL Update: Priority Cases to Watch in 2025

Current Mass Tort MDL Landscape: November 2025

Here is a snapshot of the most significant multidistrict litigations (MDLs) currently progressing through the federal court system.

Priority MDLs

GLP-1 Weight Loss Drugs (E.D. Pennsylvania)

• Ozempic, Wegovy, and similar medications
• Claims of gastroparesis and severe stomach issues
• Rapidly growing plaintiff count

Depo-Provera Brain Tumors (N.D. Florida)

• Contraceptive injection linked to meningioma brain tumors
• Scientific evidence strengthening plaintiff claims
• Significant case development expected

AFFF/PFAS Contamination (D.S.C.)

• Firefighting foam contamination
• Water contamination affecting communities nationwide
• Major settlements being negotiated

Paraquat (S.D. Illinois)

• Herbicide linked to Parkinson's disease
• Strong scientific evidence supporting causation
• Trial dates approaching

Social Media Adolescent Addiction (N.D. California)

• Claims against major platforms
• Focus on harm to teenage users
• Mental health injury allegations

New Antitrust MDLs

Two new antitrust MDLs are awaiting leadership appointment:

• Archery Products litigation
• CCell cannabis vapes litigation

What This Means for Potential Claimants

If you have been affected by any of these products or situations, now is a critical time to explore your legal options. Many of these cases are approaching key deadlines or settlement negotiations.